• Medientyp: E-Artikel
  • Titel: Evaluation of three commercial assays for rapid detection of genes encoding clinically relevant carbapenemases in cultured bacteria
  • Beteiligte: Findlay, Jacqueline; Hopkins, Katie L.; Meunier, Daniele; Woodford, Neil
  • Erschienen: Oxford University Press (OUP), 2015
  • Erschienen in: Journal of Antimicrobial Chemotherapy, 70 (2015) 5, Seite 1338-1342
  • Sprache: Englisch
  • DOI: 10.1093/jac/dku571
  • ISSN: 1460-2091; 0305-7453
  • Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology ; Microbiology (medical)
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>To assess the performance of three commercial molecular assays for detecting major families of carbapenemases in pure bacterial isolates.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A panel of 450 isolates with previously defined carbapenem resistance mechanisms was tested using the Check-Direct CPE kit, the eazyplex® SuperBug complete A kit and the Xpert® Carba-R kit. Isolates included 438 Enterobacteriaceae and 12 Pseudomonas spp. comprising 100 isolates each with KPC, NDM, VIM or OXA-48-like enzymes, two isolates producing both an NDM and an OXA-48-like enzyme, 24 IMP producers and 24 isolates without a known carbapenemase gene. Discordant results (commercial versus in-house) were investigated using in-house PCR and amplicons were sequenced to define the carbapenemase allele present.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>All three commercial assays detected all isolates with KPC, VIM, NDM and classic OXA-48 carbapenemases (no false-negatives). Isolates producing the OXA-181 variant (n = 18) were not detected by the Xpert® Carba-R kit or the eazyplex® SuperBug complete A kit, but were subsequently detected with modified versions of these kits. Only the Xpert® Carba-R kit could detect IMP carbapenemases, although this was limited to the IMP-1 subgroup. Invalid or false-positive results were either not observed when following the manufacturer's protocols or were eliminated by making simple interpretative adjustments to allow use with bacterial isolates rather than clinical samples.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Commercial assays offer a reliable means of detecting bacteria with clinically significant carbapenemases. Coverage of some assays required expansion to maximize the sensitivity for OXA-48-like carbapenemases. Choice will ultimately depend on preferred gene coverage, intended throughput, cost and ability to fit into local workflows.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang